FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention provides a method for preparing a pharmaceutical composition which is a tablet and contains a crystalline form of the tofogliflozin monohydrate as an active ingredient. Method involves mixing an auxiliary substance and a tofogliflozin monohydrate for preparing a powdered mixture and preparing the tablet from the powder mixture by direct pressing. Adjuvant contains filler, a disintegrating agent and a sliding agent. Crystalline form of tofogliflozin monohydrate includes crystalline form I, crystalline form II or mixture thereof. Composition practically does not contain calcium silicate. Preferably, the pharmaceutical composition, which is a tablet obtained using the described method, includes lactose hydrate, crystalline cellulose, sodium croscarmellose and hydrogenated oil and/or magnesium stearate as auxiliary components.
EFFECT: tofogliflozin monohydrate tablet obtained by direct pressing is characterized by improved disintegration and solubility properties.
10 cl, 4 dwg, 17 tbl, 12 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREPARING MEDICINAL AGENT CONTAINING VARDENAFIL HYDROCHLORIDE TRIHYDRATE | 2008 |
|
RU2493849C2 |
PHARMACEUTICAL COMPOSITIONS WITH CDC7 INHIBITOR | 2019 |
|
RU2810927C2 |
PHARMACEUTICAL COMBINED DRUG | 2014 |
|
RU2639818C2 |
TABLET CONTAINING 5-HYDROXY-1H-IMIDAZOLE-4-CARBOXAMIDE | 2014 |
|
RU2654703C2 |
SOLID PHARMACEUTICAL COMPOSITION CONTAINING 1-(3-(2-(1-BENZOTHIOPHENE-5-YL)ETOXY)PROPYL)AZETIDINE-3-OL OR ITS SALT | 2013 |
|
RU2625767C2 |
DOSAGE FORM OF CLOPIDOGREL | 2013 |
|
RU2540519C2 |
DRUG FORMS OF IRON (III) CITRATE | 2010 |
|
RU2563819C2 |
COMPOSITION OF SOLID QUICK-DISINTEGRATING TABLET | 2008 |
|
RU2472493C2 |
MEDICINAL FORMS OF FERRIC CITRATE (III) | 2010 |
|
RU2733410C2 |
HARD MEDICATION | 2006 |
|
RU2426530C2 |
Authors
Dates
2019-09-13—Published
2014-12-26—Filed